Plegridy approved for relapsing remitting MS in England


23 January 2020

NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing remitting MS.

In May 2018, NICE carried out a review of several of the MS drugs and decided that Avonex, Extavia, Rebif, Copaxone and Brabio should continue to be available on the NHS in England. At the time, NICE was unable to make a recommendation on Plegridy and has now completed a separate appraisal.

The MS Trust contributed throughout the process.

We are pleased that NICE has approved Plegridy for people with relapsing remitting MS. We were able to make a strong case to NICE thanks to those of you who told us about your experiences of taking this treatment and the importance of having a greater choice of disease modifying drugs.

- David Martin, Chief Executive Officer, MS Trust

Plegridy (peginterferon beta 1a) is a disease modifying drug for relapsing remitting MS which you inject once a fortnight. Plegridy is already approved for use in Scotland and Wales.

Find out more about Plegridy.

Find out more